• Connect with us at the FACHC 2017 Annual Meeting

      The RxStrategies team will be connecting with industry leaders July 16-19 in St. Petersburg, Florida for the Florida Association of Community Health Centers 2017 Annual Meeting and Education Summit. At the conference, we will be linking with professionals dedicated to providing quality community-based health care programs in Florida and discussing integrated 340B program management… Read more »

  • Clinical Insights: June 23, 2017

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Bevyxxa™ (betrixaban) – June 23, 2017 – The U.S. Food and Drug Administration approved betrixaban (Bevyxxa™, Portola) for the prophylaxis of venous thromboembolism (VTE) in adult patients… Read more »

  • Clinical Insights: June 16, 2017

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Fibryna® (fibrinogen – [human]) – June 7, 2017 – A human fibrinogen concentrate indicated for the treatment of acute bleeding episodes in adults and adolescents with congenital… Read more »

  • Clinical Insights: June 2, 2017

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Rebinyn® (Coagulation Factor IX (Recombinant), GlycoPEGylated) – May 31, 2017 – Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application… Read more »

  • Clinical Insights: May 26, 2017

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Kevzara® (sarilumab) – May 22, 2017 – Regeneron Pharmaceuticals, Inc. and Sanofi announced the U.S. Food and Drug Administration (FDA) approval of Kevzara® (sarilumab) for the treatment of… Read more »

  • May 2017 – 340B Insider

    Welcome to the May edition of RxStrategies’ 340B Insider, a concise communication to provide a quick highlight of updates from RxStrategies’ view.    CELEBRATING 25 YEARS OF THE 340B PROGRAM RxStrategies Supports Conference as Pinnacle Leader Sponsor July 10 – 12 | Washington, D.C. This year marks 25 years with the 340B program in place! Along… Read more »

  • Maximize Your Savings with Split Billing

    RxStrategies’ 340BPlus Split Billing Solution provides end-to-end 340B program management with a focus on program compliance. The 340BPlus Split Billing Solution takes the complexity out of 340B program management by reviewing all prescription activity to flag eligible 340B dispenses. All activity is then designated for proper replenishment, (GPO, WAC, 340B) auditability and reporting.    RxStrategies’ 340BPlus Split Billing… Read more »

  • RxStrategies’ Integrated 340B Solutions

    At RxStrategies, we work to remove the challenges organizations face when implementing 340B Drug Pricing Programs and make application possible by providing accountability, transparency and value-based 340B solutions. Our three main solutions: 340BPlus Split Billing Our Split Billing solution provides end-to-end 340B program management with a focus on program compliance. Manage, track, review and report… Read more »